Neurogene stops Batten gene therapy after FDA denies request, dealing double dose of bad news Read more 

Incyte's $750M buyout rocked by pause on key trial, asset cull Read more 

Nearing potential FDA approval, BridgeBio shows additional positive data on ATTR-CM candidate acoramidis Read more 

2025 BioFocus Conference

This dynamic one-day conference brings together life sciences industry leaders, cutting-edge innovators, and academic experts, offering an unparalleled opportunity to stay ahead of the curve. [...]

Go to Top